Quantcast
Last updated on April 21, 2014 at 5:04 EDT

Latest Renal cell carcinoma Stories

2014-04-15 23:10:44

A new study published in The Oncologist journal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to...

2014-04-09 08:28:15

SANTA ROSA, Calif., April 9, 2014 /PRNewswire/ -- A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma. Conducted by researchers at the Cancer Research Laboratory at Indiana University Health, Indiana University School of Medicine, the preclinical study showed that honokiol (HonoPure®, EcoNugenics, Santa Rosa, CA) inhibited two highly aggressive renal cell carcinoma (RCC) cell lines....

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-03-25 23:30:00

Markets Research Reports.biz added deep and professional market research reports on "Global Cancer Vaccines Competitor Analysis And Market Research" Market Analysis and Overview. Albany, NY (PRWEB) March 25, 2014 The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to...

2014-03-11 04:21:19

WHIPPANY, N.J., THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR(®) (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not...

2014-03-04 12:26:52

Incentives for Pathway Compliance, Reduced Hospitalization are Changing Treatment, According to Findings from Decision Resources Group BURLINGTON, Mass., March 4, 2014 /PRNewswire/ -- Decision Resources Group finds that the increasing use of clinical pathway programs, accountable care organizations (ACOs) and bundled payments is changing the prescribing of oncology drugs in the treatment of colorectal cancer and renal cell carcinoma. As more payers and oncology practices adopt pathways,...

2014-03-04 12:25:51

SAN DIEGO and OSAKA, Japan, March 4, 2014 /PRNewswire/ -- TRACON Pharmaceuticals (TRACON) and Santen Pharmaceutical Co., Ltd. (Santen) announced today that they have entered into an exclusive agreement for the development and global commercialization of TRACON's anti-endoglin antibodies, including TRC105, in ophthalmology. Pre-clinical and clinical data from TRACON's ongoing development of TRC105 in combination with anti-VEGF products in oncology indicate inhibiting both the...

2014-02-24 08:29:21

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 /PRNewswire/ -- Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics in cancer, today announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and...

2014-02-03 04:20:02

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood...